logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Promising Agreement Between Jazz Pharmaceuticals and Werewolf Therapeutics

Jazz Pharmaceuticals and Werewolf Therapeutics Agreement Jazz Pharmaceuticals ( JAZZ ) and Werewolf Therapeutics ( HOWL ) entered into a licensing agreement under which Jazz has acquired exclusive global development and commercialization rights to Werewolf's investigational WTX-613, a differentiated, conditionally-activated interferon alpha...

Read More

April 8, 2022

0

Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

Gilead Sciences' Lenacapavir Demonstrated 100% Efficacy in Preventing HIV Gilead Sciences, Inc. ( GILD ) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable HIV-1 capsid inhibitor,...

Read More

June 20, 2024

0

Novo Nordisk Aims to Acquire Cardior Pharmaceuticals, Strengthening Its Pipeline in Cardiovascular Disease

Novo Nordisk in the NEWS Novo Nordisk ( NVO ) and Cardior Pharmaceuticals announced that Novo Nordisk agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones...

Read More

March 25, 2024

0

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients

Sarepta Therapeutics in the NEWS On June 20, 2024, Sarepta Therapeutics ( SRPT ) announced that the U. S. FDA has approved an expansion to the labeled indication for ELEVIDYS (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD)...

Read More

June 21, 2024

0

Alnylam Pharmaceuticals: Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran

Alnylam Pharamceuticals Announcement June 24, 2024, Alnylam Pharmaceuticals ( ALNY ) announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy ( ATTR-CM )....

Read More

June 24, 2024

0

BioStem Technologies is Releasing its Fourth Quarter 2023 Financial Results Now

BioStem Technologies to Release Fourth Quarter Results BioStem Technologies ( BSEM ) is hosting a conference call and webcast today, April 1, 2024 at 4:30 PM ET. The call will include a discussion of fourth quarter 2023 financial results in...

Read More

April 1, 2024

0

Gilead Sciences: Remdesivir is the First and Only Approved Treatment for Pediatric Patients with COVID-19. See Also: Cassava Sciences

Gilead Sciences Receives sNDA from the FDA for Remdesivir for Pediatric Patients with COVID-19 Gilead Sciences ( GILD ) announced that the U.S. Food and Drug Administration ( FDA ) has approved a supplemental new drug application ( sNDA )...

Read More

April 26, 2022

0

Johnson & Johnson to Acquire Shockwave Medical

Johnson & Johnson in the NEWS Today, Apr. 5, 2024 - Johnson & Johnson ( JNJ ) and Shockwave Medical ( SWAV ) announced that they entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding...

Read More

April 5, 2024

0

Amgen: Repatha Studies Showed Sustained Reduction in Low-Density Lipoprotein Cholesterol with No New Safety Findings

Amgen Repatha Studies Repatha is the Longest Studied PCSK9i Amgen ( AMGN ) announced top-line results from two Repatha® (evolocumab) open label extension ( OLE ) studies to the Phase 3 FOURIER cardiovascular outcomes trial. The studies were designed to assess...

Read More

April 27, 2022

0

Madrigal Pharmaceuticals Announces U.S. Availability of its Newly Approved Product Rezdiffra

Madrigal Pharmaceuticals in the NEWS Today, April 09, 2024, Madrigal Pharmaceuticals ( MDGL ) announced that its NASH MASH product Rezdiffra ( resmetirom ) is now available in the United States. Rezdiffra is indicated in conjunction with diet and exercise...

Read More

April 9, 2024

0

  • Previous
  • 1
  • 2
  • ...
  • 157
  • 158
  • 159
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy